Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...
A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...
Adding the personalized mRNA therapy intismeran autogene to Keytruda cut melanoma recurrence and spread risk after surgery, a Phase 3 trial found. A Phase 3 trial found that adding the individualized ...
Merck and Moderna say the experimental treatment extended the time before skin cancer returned in patients at high risk.
Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the ...
A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever ...
The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.
Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results